[ Harpoon Therapeutics raises $45M in Series B ]
Harpoon Therapeutics has raised $45 million in Series B funding.
Founded in 2015, Harpoon Therapeutics is a biotechnology company developing novel T-cell recruiting biologic therapies for the treatment of cancer.
Proceeds from the financing will be used to advance Harpoon Therapeutics’ novel, proprietary, tri-specific T-cell activating construct (TriTAC™) immuno-oncology platform, including moving two lead programs into clinical trials and expanding the product pipeline through discovery and partnering initiatives.
|Founder / CEO||Gerald McMahon|
|New Leaf Venture Partners|
|Previous Investors||MPM Capital|